Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    18445842 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed
Has Results
Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma
Conditions: Cancer;   Melanoma
Interventions: Drug: Sorafenib (Nexavar, BAY43-9006);   Drug: Placebo;   Drug: Dacarbazine

Indicates status has not been verified in more than two years